Ten months after pledging to expand a discount program for a drug that treats an HIV-related infection, Gilead Sciences (GILD) has registered its medicine in just six of 116 designated countries and, in some cases, failed to lower the price as promised, according to Doctors Without Borders. And the non-governmental organization is accusing the company of running a “public relations stunt.”

At issue is an injectable medication called AmBisome that is used to combat cryptococcal meningitis, which is the second biggest killer of people living with HIV, after tuberculosis, according to the group. And the World Health Organization estimates the infection is responsible for 15% of HIV-related deaths globally.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy